| Name | Title | Contact Details |
|---|
Vestiage, Inc. exists to cultivate healthy-aging opportunities for all men and women and to nurture those opportunities with wholesome products, people, and practices. Currently we offer multiple products through two brands: RegiMEN and Monterey Bay. We do what we do because life deserves vitality and we're excited to share with you, learn from you, and grow together.
VetEvolve offers relationship-focused veterinary practice acquisition that helps you put the focus back on your patients with our superior business management.
A premier provider of high quality, behavioral health care founded in 1999 and headquartered in central Pennsylvania, we operate over 80 facilities across the Commonwealth, New Jersey, and North Carolina and offer a full continuum of mental health, treatment and recovery services for adults and teens. Our dedicated admissions representatives are available to schedule confidential assessments and admissions, recommend appropriate treatment options, assist with insurance verification and facilitate complimentary transportation to and from our detox and inpatient program locations.
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.
The Office of the National Coordinator for Health Information Technology (ONC) is the lead agency charged with formulating the federal government’s health IT strategy and coordinating federal health IT policies, standards, programs, and investments. ONC is organizationally located within the Office of the Secretary for the U.S. Department of Health and Human Services (HHS). The position of National Coordinator was created in 2004, through an Executive Order, and legislatively mandated in the Health Information Technology for Economic and Clinical Health Act (HITECH Act) of 2009.